Compare Amphastar Pharmaceuticals Inc (AMPH) vs General Mills, Inc. (GIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs General Mills, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while General Mills, Inc. trades at $36.31 (market cap $19.33B). The key difference: General Mills, Inc. is far larger — about 23.4× Amphastar Pharmaceuticals Inc's market cap, and General Mills, Inc. pays a 6.74% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | GIS | |
|---|---|---|
Market Cap | $826.08M | $19.33B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $51.60 |
52-Week Low | $16.87 | $32.17 |
Enterprise Value | $1.22B | $32.82B |
Dividend Yield | — | 6.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
General Mills (GIS) trades at $36.22, up 1.03% on the day, near the analyst consensus price target of $36.14. The stock presents a mixed picture with a low P/E of 9.23 suggesting value, but profitability metrics like a negative net income margin and ROE for 2026 signal challenges. Recent Q2 2026 earnings beat expectations, yet the technical outlook is bearish, and news highlights sales pressure and a focus on cost savings to drive a margin recovery in fiscal 2027.
The investment outlook is cautious. The stock's low valuation and dividend yield offer potential value, but persistent sales softness, margin pressure from competition, and a high debt-to-asset ratio of 45% pose significant risks. Analyst sentiment is predominantly neutral to negative, with a majority hold rating, indicating a wait-and-see approach is warranted until clearer signs of sustainable growth emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
